Drug
Ridaforolimus clinical trials
Also written MK-8669, AP23573 and deforolimus.
- studies test it
- 33
- open now
- 0
- in phase 3
- 1
- first study started
- 2003
How studies write it
Studies that test it under each name
Name
Other names
Combined with it in one product
Studies by the year they started
33 studies that test it; most in 2008 (8)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 8 |
| 2009 | 3 |
| 2010 | 7 |
| 2011 | 3 |
| 2012 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 21
- Phase 2
- 11
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 28 · Other 5
Merck Sharp & Dohme LLC (28) · NCIC Clinical Trials Group (1) · Fox Chase Cancer Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Angela Taber MD (1) · The University of Texas Health Science Center at San Antonio (1)
Often tested with
Tested in the same studies.
Dalotuzumab (3) · Vorinostat (1) · Paclitaxel (1) · Carboplatin (1) · Trastuzumab (1) · Doxorubicin (1) · Bevacizumab (1) · MK-0752 (1)
Studies
Open first, then newest update. How each study uses ridaforolimus is read from its arms, and is right about nine times in ten.
Testing it · 33
- Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)CompletedPhase 1Merck Sharp & Dohme LLCNCT00694083Written as Ridaforolimus
- Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial CancerCompletedPhase 2NCIC Clinical Trials GroupNCT00770185Written as ridaforolimus
- Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or LymphomaCompletedPhase 1Fox Chase Cancer CenterNCT01169532Written as ridaforolimus
- Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck CancerTerminatedPhase 1Angela Taber MDNCT01212627Written as Ridaforolimus
- A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)CompletedPhase 1Merck Sharp & Dohme LLCNCT00874731Written as Ridaforolimus 100 mg
- Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)CompletedPhase 1Merck Sharp & Dohme LLCNCT01380184Written as ridaforolimus
- A Study of Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-056)TerminatedPhase 1Merck Sharp & Dohme LLCNCT01431534Written as Ridaforolimus
- Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)TerminatedPhase 2Merck Sharp & Dohme LLCNCT00836927Written as Ridaforolimus Tablet
- A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)TerminatedPhase 1Merck Sharp & Dohme LLCNCT01243762Written as ridaforolimus
- Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and SolidsCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT01256268Written as Ridaforolimus
- A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)CompletedPhase 2Merck Sharp & Dohme LLCNCT01234857Written as ridaforolimus + dalotuzumab
- Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)CompletedPhase 1Merck Sharp & Dohme LLCNCT01431547Written as ridaforolimus
- Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)CompletedPhase 2Merck Sharp & Dohme LLCNCT00110188Written as ridaforolimus
- Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)CompletedPhase 2Merck Sharp & Dohme LLCNCT00736970Written as ridaforolimus
- Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)CompletedPhase 1Merck Sharp & Dohme LLCNCT00060632Written as ridaforolimus
- Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)CompletedPhase 1Merck Sharp & Dohme LLCNCT00060645Written as ridaforolimus
- Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)CompletedPhase 2Merck Sharp & Dohme LLCNCT00086125Written as ridaforolimus
- Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)CompletedPhase 2Merck Sharp & Dohme LLCNCT00777959Written as ridaforolimus (MK8669)
- Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)CompletedPhase 1Merck Sharp & Dohme LLCNCT00087451Written as AP23573
- Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)CompletedPhase 1Merck Sharp & Dohme LLCNCT00288431Written as ridaforolimus
See all 33 studies that test ridaforolimus →
Given in every arm · 2 — ridaforolimus is usual care beside what is tested
- A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)CompletedPhase 2Merck Sharp & Dohme LLCNCT01605396Written as Ridaforolimus
- Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)CompletedPhase 1Merck Sharp & Dohme LLCNCT01295632Written as ridaforolimus
Codes
What other systems call ridaforolimus · ClinicalTrials.gg INT004996
- MeSH (NLM) C515074ridaforolimusOne source NLM
- UNII (FDA) 48Z35KB15KRIDAFOROLIMUSConfirmed FDA, NLM, Wikidata
- Wikidata Q2151796ridaforolimusConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C49061RidaforolimusOne source FDA
- DrugBank DB06233One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C515074 | ridaforolimus | One source NLM |
| UNII (FDA) | 48Z35KB15K | RIDAFOROLIMUS | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q2151796 | ridaforolimus | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C49061 | Ridaforolimus | One source FDA |
| DrugBank | DB06233 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.